- Home
- BCG vs RNXT Comparison
BCG vs RNXT Comparison
Compare BCG & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- RNXT
- Stock Information
- Founded
- BCG 2016
- RNXT 2012
- Country
- BCG United States
- RNXT United States
- Employees
- BCG N/A
- RNXT N/A
- Industry
- BCG
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- RNXT Health Care
- Exchange
- BCG Nasdaq
- RNXT Nasdaq
- Market Cap
- BCG 41.3M
- RNXT 44.6M
- IPO Year
- BCG N/A
- RNXT 2021
- Fundamental
- Price
- BCG $2.00
- RNXT $1.30
- Analyst Decision
- BCG
- RNXT Strong Buy
- Analyst Count
- BCG 0
- RNXT 2
- Target Price
- BCG N/A
- RNXT $7.25
- AVG Volume (30 Days)
- BCG 8.9K
- RNXT 135.9K
- Earning Date
- BCG 08-14-2025
- RNXT 08-12-2025
- Dividend Yield
- BCG N/A
- RNXT N/A
- EPS Growth
- BCG N/A
- RNXT N/A
- EPS
- BCG N/A
- RNXT N/A
- Revenue
- BCG $172,860,000.00
- RNXT $240,000.00
- Revenue This Year
- BCG N/A
- RNXT $3,104.65
- Revenue Next Year
- BCG N/A
- RNXT $301.89
- P/E Ratio
- BCG N/A
- RNXT N/A
- Revenue Growth
- BCG 7.36
- RNXT N/A
- 52 Week Low
- BCG $1.71
- RNXT $0.75
- 52 Week High
- BCG $6.55
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- RNXT 53.41
- Support Level
- BCG N/A
- RNXT $1.29
- Resistance Level
- BCG N/A
- RNXT $1.38
- Average True Range (ATR)
- BCG 0.00
- RNXT 0.07
- MACD
- BCG 0.00
- RNXT -0.01
- Stochastic Oscillator
- BCG 0.00
- RNXT 48.39
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.